Table 3 Treatment-related adverse events during treatment with immune checkpoint inhibitors.
Treatment-related adverse events # | Overall (n = 42) | Pembrolizumab (n = 19) | Maintenance avelumab (n = 13) | Adjuvant nivolumab (n = 10) | ||||
|---|---|---|---|---|---|---|---|---|
Grade 2 ≤ | Grade 3 ≤ | Grade 2 ≤ | Grade 3 ≤ | Grade 2 ≤ | Grade 3 ≤ | Grade 2 ≤ | Grade 3 ≤ | |
Any ## | 23 (55%) | 4 (9.5%) | 9 (47%) | 2 (11%) | 7 (54%) | 1 (7.7%) | 7 (70%) | 0 |
Myelosuppression | 1 (2.4%) | 0 | 0 | 0 | 1 (7.7%) | 0 | 0 | 0 |
Gastrointestinal disorder | 3 (7.1%) | 0 | 1 (5.3%) | 0 | 1 (7.7%) | 0 | 1 (10%) | 0 |
Fatigue | 1 (2.4%) | 1 (2.4%) | 1 (5.3%) | 1 (5.3%) | 0 | 0 | 0 | 0 |
Hepatotoxicity | 2 (4.8%) | 0 | 2 (11%) | 0 | 0 | 0 | 0 | 0 |
Dermatoxicity | 7 (17%) | 1 (2.4%) | 2 (11%) | 0 | 4 (31%) | 1 (7.7%) | 1 (10%) | 0 |
Interstitial lung disease | 4 (9.5%) | 0 | 3 (16%) | 0 | 0 | 0 | 1 (10%) | 0 |
Colitis | 2 (4.8%) | 0 | 1 (5.3%) | 0 | 0 | 0 | 1 (10%) | 0 |
Endocrine disorders | 10 (24%) | 2 (4.8%) | 5 (26%) | 1 (5.3%) | 1 (7.7%) | 0 | 4 (40%) | 1 (10%) |
Type 1 diabetes | 1 (2.4%) | 0 | 0 | 0 | 1 (7.7%) | 0 | 0 | 0 |